Demographic and clinical characteristics of the study population
| Characteristic . | DC (n = 35) . | NC (n = 38) . | CC (n = 35) . | DC vs NC P‡ . | DC vs CC P‡ . |
|---|---|---|---|---|---|
| Age, y | |||||
| Male partners | 46 (38-52) | 42 (35-49) | 47 (41-53) | .194 | .502 |
| Female partners | 34 (29-40) | 36 (30-41) | 33 (29-40) | .510 | .606 |
| Senegalese origin, n (%)* | |||||
| Male partners | 31 (89) | 36 (95) | 33 (94) | .418 | .673 |
| Female partners | 32 (91) | 36 (95) | 34 (97) | .666 | .614 |
| Duration of sexual relation, y† | 8 (4-15) | 8 (4-16) | 10 (6-13) | .782 | .259 |
| Sexual contacts/mo† | 5 (4-8) | 8 (3-12) | 8 (4-12) | .536 | .199 |
| Condom use, n (%)† | |||||
| Never | 5 (15) | 29 (78) | 10 (29) | < .001 | .010 |
| < 50% of the time | 4 (12) | 7 (19) | 13 (37) | ||
| > 50% of the time | 1 (3) | 0 (0) | 1 (3) | ||
| Always | 24 (71) | 1 (3) | 11 (31) | ||
| Male index partners, n (%) | 16 (46) | NA | 33 (94) | NA | < .001 |
| Time since HIV diagnosis, y | |||||
| Index partners | 2.0 (0.7-4.9) | NA | 3.0 (0.8-5.1) | NA | .386 |
| Recipient partners | NA | NA | 2.3 (0.6-3.5) | NA | NA |
| Antiretroviral therapy, n (%) | |||||
| Index partners | 27 (77) | NA | 27 (79) | NA | .819 |
| Recipient partners | NA | NA | 16 (46) | NA | NA |
| CD4 count, cells/μL | |||||
| Index partners | 227 (70-366) | NA | 239 (184-345) | NA | .247 |
| Recipient partners | NA | NA | 309 (242-522) | NA | NA |
| Viral load, log10 copies/mL | |||||
| Index partners | 1.8 (1.7-4.3) | NA | 1.7 (1.7-4.0) | NA | .714 |
| Recipient partners | NA | NA | 3.4 (1.7-4.9) | NA | NA |
| Characteristic . | DC (n = 35) . | NC (n = 38) . | CC (n = 35) . | DC vs NC P‡ . | DC vs CC P‡ . |
|---|---|---|---|---|---|
| Age, y | |||||
| Male partners | 46 (38-52) | 42 (35-49) | 47 (41-53) | .194 | .502 |
| Female partners | 34 (29-40) | 36 (30-41) | 33 (29-40) | .510 | .606 |
| Senegalese origin, n (%)* | |||||
| Male partners | 31 (89) | 36 (95) | 33 (94) | .418 | .673 |
| Female partners | 32 (91) | 36 (95) | 34 (97) | .666 | .614 |
| Duration of sexual relation, y† | 8 (4-15) | 8 (4-16) | 10 (6-13) | .782 | .259 |
| Sexual contacts/mo† | 5 (4-8) | 8 (3-12) | 8 (4-12) | .536 | .199 |
| Condom use, n (%)† | |||||
| Never | 5 (15) | 29 (78) | 10 (29) | < .001 | .010 |
| < 50% of the time | 4 (12) | 7 (19) | 13 (37) | ||
| > 50% of the time | 1 (3) | 0 (0) | 1 (3) | ||
| Always | 24 (71) | 1 (3) | 11 (31) | ||
| Male index partners, n (%) | 16 (46) | NA | 33 (94) | NA | < .001 |
| Time since HIV diagnosis, y | |||||
| Index partners | 2.0 (0.7-4.9) | NA | 3.0 (0.8-5.1) | NA | .386 |
| Recipient partners | NA | NA | 2.3 (0.6-3.5) | NA | NA |
| Antiretroviral therapy, n (%) | |||||
| Index partners | 27 (77) | NA | 27 (79) | NA | .819 |
| Recipient partners | NA | NA | 16 (46) | NA | NA |
| CD4 count, cells/μL | |||||
| Index partners | 227 (70-366) | NA | 239 (184-345) | NA | .247 |
| Recipient partners | NA | NA | 309 (242-522) | NA | NA |
| Viral load, log10 copies/mL | |||||
| Index partners | 1.8 (1.7-4.3) | NA | 1.7 (1.7-4.0) | NA | .714 |
| Recipient partners | NA | NA | 3.4 (1.7-4.9) | NA | NA |
Data are obtained at enrollment of the couples and are representative of that moment. Data are median values (interquartile range) or n (%) when indicated.
DC indicates HIV-1–discordant couples; NC, HIV-negative couples; CC, HIV-1–concordant couples; and NA, not applicable.
Other countries of origin were Guinea, Sierra Leone, Mali, Togo, Guinea Bissau, and Mauretania.
Based on female partners' data; comparable results were obtained when male partners' data were analyzed.
Categorical data were analyzed with χ2 tests or Fisher exact tests when cells had expected counts less than 5. Continuous data were analyzed with Mann-Whitney U tests. P values < .05 are in bold.